# Reblozyl

NDC: 59572-775
Generic name: Luspatercept
Labeler / Manufacturer: Celgene Corporation
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Routes: SUBCUTANEOUS
Marketing started: 20191108

FDA application: BLA761136

## Active ingredients

- LUSPATERCEPT: 75 mg/1

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"59572-775"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=59572-775
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=82f4d266-3f52-41eb-86ba-0abf3cf468e8